This bill allows for the omission of certain information relating to the strength of a product in a biosimilar application, as determined by the Food and Drug Administration.
Actions
Mar 10, 2022
Referred to the Subcommittee on Health.
Mar 9, 2022
Referred to the House Committee on Energy and Commerce.